Response rates and minimal residual disease outcomes as potential surrogates for progression-free survival in newly diagnosed multiple myeloma

Progression-free survival (PFS) is a common primary endpoint in newly diagnosed multiple myeloma (NDMM). Patients with NDMM typically have longer PFS and are more likely to achieve minimal residual disease (MRD) or complete response (CR) compared to patients with relapsed or refractory multiple myel...

Descripción completa

Detalles Bibliográficos
Autores principales: Daniele, Patrick, Mamolo, Carla, Cappelleri, Joseph C., Bell, Timothy, Neuhof, Alexander, Tremblay, Gabriel, Musat, Mihaela, Forsythe, Anna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9098007/
https://www.ncbi.nlm.nih.gov/pubmed/35550641
http://dx.doi.org/10.1371/journal.pone.0267979

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9098007/
https://www.ncbi.nlm.nih.gov/pubmed/35550641
http://dx.doi.org/10.1371/journal.pone.0267979

Ejemplares similares